EPS for Quotient Limited (QTNT) Expected At $-0.51

May 16, 2018 - By Christine McCrea

Quotient Limited (NASDAQ:QTNT) LogoInvestors sentiment increased to 1.93 in 2017 Q4. Its up 0.51, from 1.42 in 2017Q3. It is positive, as 5 investors sold Quotient Limited shares while 10 reduced holdings. 7 funds opened positions while 22 raised stakes. 30.23 million shares or 41.49% more from 21.37 million shares in 2017Q3 were reported.
Schwab Charles Inv Management holds 46,200 shares. Moreover, Sio Management Limited Co has 3.98% invested in Quotient Limited (NASDAQ:QTNT). Jpmorgan Chase And has 5,768 shares for 0% of their portfolio. Cormorant Asset Limited Com owns 4.49M shares. Ameriprise Financial holds 0% or 2.15 million shares in its portfolio. Citigroup reported 3,157 shares. Geode Cap Mngmt Lc has 0% invested in Quotient Limited (NASDAQ:QTNT) for 75,232 shares. Wells Fargo & Mn holds 0% of its portfolio in Quotient Limited (NASDAQ:QTNT) for 33,961 shares. Clearbridge accumulated 2.56 million shares. Colony Gru Limited Liability Company holds 0% or 13,360 shares in its portfolio. Polar Capital Limited Liability Partnership, a United Kingdom-based fund reported 6.80M shares. Moreover, Tiaa Cref Management Lc has 0% invested in Quotient Limited (NASDAQ:QTNT) for 75,241 shares. Macquarie Grp Incorporated accumulated 6,000 shares or 0% of the stock. Vanguard Grp Incorporated has invested 0% in Quotient Limited (NASDAQ:QTNT). Millennium Mngmt Limited Liability Corporation reported 503,735 shares or 0% of all its holdings.

Since February 21, 2018, it had 1 insider purchase, and 0 insider sales for $51,348 activity.

Analysts expect Quotient Limited (NASDAQ:QTNT) to report $-0.51 EPS on May, 28.They anticipate $0.18 EPS change or 26.09 % from last quarter’s $-0.69 EPS. After having $-0.47 EPS previously, Quotient Limited’s analysts see 8.51 % EPS growth. The stock decreased 0.85% or $0.04 during the last trading session, reaching $4.65. About 190,152 shares traded. Quotient Limited (NASDAQ:QTNT) has declined 24.44% since May 17, 2017 and is downtrending. It has underperformed by 35.99% the S&P500.

Quotient Limited, a commercial-stage diagnostics company, develops, makes, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company has market cap of $211.99 million. The firm is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. It currently has negative earnings. It also develops, makes, and commercializes conventional reagent products for blood grouping, including antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping.

More news for Quotient Limited (NASDAQ:QTNT) were recently published by: Globenewswire.com, which released: “Quotient Limited to Report Fourth Quarter and Fiscal Full Year 2018 Financial Results and Host Conference Call” on May 15, 2018. Streetinsider.com‘s article titled: “Quotient (QTNT) Announces FDA Approval of Seven Blood Bank Reagents, Including Two Market Firsts” and published on April 24, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: